These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. Good MF; Hawkes MT mBio; 2020 Oct; 11(5):. PubMed ID: 33097654 [TBL] [Abstract][Full Text] [Related]
63. Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends". Kleen TO; Galdon AA; MacDonald AS; Dalgleish AG Front Immunol; 2020; 11():2059. PubMed ID: 33013871 [TBL] [Abstract][Full Text] [Related]
65. Understanding COVID-19 vaccine efficacy. Lipsitch M; Dean NE Science; 2020 Nov; 370(6518):763-765. PubMed ID: 33087460 [No Abstract] [Full Text] [Related]
66. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Graepel KW; Kochhar S; Clayton EW; Edwards KE J Infect Dis; 2020 Jun; 222(2):180-182. PubMed ID: 32365191 [No Abstract] [Full Text] [Related]
67. Cell and animal models of SARS-CoV-2 pathogenesis and immunity. Leist SR; Schäfer A; Martinez DR Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32887790 [TBL] [Abstract][Full Text] [Related]
68. Inclusion of pregnant women in COVID-19 vaccine development. Heath PT; Le Doare K; Khalil A Lancet Infect Dis; 2020 Sep; 20(9):1007-1008. PubMed ID: 32795409 [No Abstract] [Full Text] [Related]
71. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frederiksen LSF; Zhang Y; Foged C; Thakur A Front Immunol; 2020; 11():1817. PubMed ID: 32793245 [TBL] [Abstract][Full Text] [Related]
72. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Kanduc D; Shoenfeld Y Immunol Res; 2020 Oct; 68(5):310-313. PubMed ID: 32946016 [No Abstract] [Full Text] [Related]
73. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298 [TBL] [Abstract][Full Text] [Related]
74. Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics. Mellors J; Tipton T; Longet S; Carroll M Front Immunol; 2020; 11():1450. PubMed ID: 32733480 [TBL] [Abstract][Full Text] [Related]
75. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. McAteer J; Yildirim I; Chahroudi A Clin Infect Dis; 2020 Jul; 71(15):703-705. PubMed ID: 32282038 [TBL] [Abstract][Full Text] [Related]
76. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy. Poulas K; Farsalinos K; Zanidis C Front Immunol; 2020; 11():1373. PubMed ID: 32612613 [No Abstract] [Full Text] [Related]
77. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Shih HI; Wu CJ; Tu YF; Chi CY Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623 [TBL] [Abstract][Full Text] [Related]
79. Translating Science on COVID-19 to Improve Clinical Care and Support the Public Health Response. Del Rio C; Malani P JAMA; 2020 Jun; 323(24):2464-2465. PubMed ID: 32442244 [No Abstract] [Full Text] [Related]
80. Privileges and Immunity Certification During the COVID-19 Pandemic. Hall MA; Studdert DM JAMA; 2020 Jun; 323(22):2243-2244. PubMed ID: 32374358 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]